CoChat
Sign Up
Cited by 291Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases

MEK and the inhibitors: from bench to bedside

Open access
Akinleye, Akintunde, Furqan, Muhammad, Mukhi, Nikhil, Ravella, Pavan, Liu, Delong·2013·Journal of Hematology & Oncology
DOI 10.1186/1756-8722-6-27PMC PMC3626705
Open this paper in CoChat — free accountOpen PDF

Abstract

Four distinct MAP kinase signaling pathways involving 7 MEK enzymes have been identified. MEK1 and MEK2 are the prototype members of MEK family proteins. Several MEK inhibitors are in clinical trials. Trametinib is being evaluated by FDA for the treatment of metastatic melanoma with BRAF V600 mutation. Selumetinib has been studied in combination with docetaxel in phase II randomized trial in previously treated patients with advanced lung cancer. Selumetinib group had better response rate and progression-free survival. This review also summarized new MEK inhibitors in clinical development, including pimasertib, refametinib, PD-0325901, TAK733, MEK162 (ARRY 438162), RO5126766, WX-554, RO4987655 (CH4987655), GDC-0973 (XL518), and AZD8330.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1756-8722-6-27

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Cell morphology and fluorescent reporters have been used to measure or infer cell states in migrating cells.

    “Cell morphology42 and fluorescent reporters44 have been used to measure or infer cell states in migrating cells.”

    From Inference of weak-form partial differential equations describing migration and proliferation mechanisms in wound healing experiments on cancer cells (2025) · cites this paper as [44]

    Citation 44 is attached to the fluorescent-reporters part of the sentence, not to cell morphology. The Introduction and MEK proteins sections discuss MAPK signaling and cell motility, but no passage found describes fluorescent reporters being used to measure or infer states in migrating cells (searched: fluorescent reporters, fluorescence, reporter assay, migration). (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 102

  1. Chang L Karin M Mammalian MAP kinase signalling cascades Nature 2001 410 6824 37 40 11242034
  2. Thompson N Lyons J Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery Curr Opin Pharmacol 2005 5 4 350 356 15955734
  3. Hsueh C-T Liu D Wang H Novel biomarkers for diagnosis, prognosis, targeted therapy and clinical trials Biomarker Res 2013 1 1 1 PMC3776243 24252729
  4. Furqan M Mukhi N Lee B Liu D Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application Biomarker Res 2013 1 1 5 PMC3776247 24252238
  5. Lee B Mukhi N Liu D Current management and novel agents for malignant melanoma J Hematol Oncol 2012 5 3 22333219 PMC3293076
  6. Fischmann TO Smith CK Mayhood TW Myers JE Reichert P Mannarino A Carr D Zhu H Wong J Yang RS Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors Biochemistry 2009 48 12 2661 2674 19161339
  7. Takekawa M Tatebayashi K Saito H Conserved docking site is essential for activation of mammalian MAP kinase kinases by specific MAP kinase kinase kinases Mol Cell 2005 18 3 295 306 15866172
  8. Liang H Liu T Chen F Liu Z Liu S A full-length 3D structure for MAPK/ERK kinase 2 (MEK2) Sci China Life Sci 2011 54 4 336 341 21509657
  9. Sacks DB The role of scaffold proteins in MEK/ERK signalling Biochem Soc Trans 2006 34 Pt 5 833 836 17052209
  10. Pylayeva-Gupta Y Grabocka E Bar-Sagi D RAS oncogenes: weaving a tumorigenic web Nat Rev Cancer 2011 11 11 761 774 21993244 PMC3632399
  11. Roskoski R Jr RAF protein-serine/threonine kinases: structure and regulation Biochem Biophys Res Commun 2010 399 3 313 317 20674547
  12. Roovers K Assoian RK Integrating the MAP kinase signal into the G1 phase cell cycle machinery Bioessays 2000 22 9 818 826 10944584
  13. Sears R Nuckolls F Haura E Taya Y Tamai K Nevins JR Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability Genes Dev 2000 14 19 2501 2514 11018017 PMC316970
  14. Hwang CY Lee C Kwon KS Extracellular signal-regulated kinase 2-dependent phosphorylation induces cytoplasmic localization and degradation of p21Cip1 Mol Cell Biol 2009 29 12 3379 3389 19364816 PMC2698740
  15. Yang JY Zong CS Xia W Yamaguchi H Ding Q Xie X Lang JY Lai CC Chang CJ Huang WC ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation Nat Cell Biol 2008 10 2 138 148 18204439 PMC2376808
  16. Balmanno K Cook SJ Tumour cell survival signalling by the ERK1/2 pathway Cell Death Differ 2009 16 3 368 377 18846109
  17. Davies H Bignell GR Cox C Stephens P Edkins S Clegg S Teague J Woffendin H Garnett MJ Bottomley W Mutations of the BRAF gene in human cancer Nature 2002 417 6892 949 954 12068308
  18. Marks JL Gong Y Chitale D Golas B McLellan MD Kasai Y Ding L Mardis ER Wilson RK Solit D Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma Cancer Res 2008 68 14 5524 5528 18632602 PMC2586155
  19. Murugan AK Dong J Xie J Xing M MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas Cell Cycle 2009 8 13 2122 2124 19411838
  20. Rampoldi L Zimbello R Bortoluzzi S Tiso N Valle G Lanfranchi G Danieli GA Chromosomal localization of four MAPK signaling cascade genes: MEK1, MEK3, MEK4 and MEKK5 Cytogenet Cell Genet 1997 78 3–4 301 303 9465908
  21. Han J Lee JD Jiang Y Li Z Feng L Ulevitch RJ Characterization of the structure and function of a novel MAP kinase kinase (MKK6) J Biol Chem 1996 271 6 2886 2891 8621675
  22. Stein B Brady H Yang MX Young DB Barbosa MS Cloning and characterization of MEK6, a novel member of the mitogen-activated protein kinase kinase cascade J Biol Chem 1996 271 19 11427 11433 8626699
  23. Virtue A Wang H Yang X-f MicroRNAs and Toll-like Receptor/Interleukin-1 Receptor Signaling J Hematol Oncol 2012 5 1 66 23078795 PMC3529674
  24. Zarubin T Han J Activation and signaling of the p38 MAP kinase pathway Cell Res 2005 15 1 11 18 15686620
  25. Brancho D Tanaka N Jaeschke A Ventura JJ Kelkar N Tanaka Y Kyuuma M Takeshita T Flavell RA Davis RJ Mechanism of p38 MAP kinase activation in vivo Genes Dev 2003 17 16 1969 1978 12893778 PMC196252
  26. Bulavin DV Fornace AJ Jr p38 MAP kinase’s emerging role as a tumor suppressor Adv Cancer Res 2004 92 95 118 15530558
  27. Bulavin DV Higashimoto Y Popoff IJ Gaarde WA Basrur V Potapova O Appella E Fornace AJ Jr Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase Nature 2001 411 6833 102 107 11333986
  28. Iyoda K Sasaki Y Horimoto M Toyama T Yakushijin T Sakakibara M Takehara T Fujimoto J Hori M Wands JR Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma Cancer 2003 97 12 3017 3026 12784337
  29. Hanks SK Quinn AM Hunter T The protein kinase family: conserved features and deduced phylogeny of the catalytic domains Science 1988 241 4861 42 52 3291115
  30. Kyriakis JM Avruch J Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation Physiol Rev 2001 81 2 807 869 11274345
  31. Eferl R Ricci R Kenner L Zenz R David JP Rath M Wagner EF Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53 Cell 2003 112 2 181 192 12553907
  32. Ip YT Davis RJ Signal transduction by the c-Jun N-terminal kinase (JNK)–from inflammation to development Curr Opin Cell Biol 1998 10 2 205 219 9561845
  33. Putcha GV Le S Frank S Besirli CG Clark K Chu B Alix S Youle RJ LaMarche A Maroney AC JNK-mediated BIM phosphorylation potentiates BAX-dependent apoptosis Neuron 2003 38 6 899 914 12818176
  34. Tournier C Hess P Yang DD Xu J Turner TK Nimnual A Bar-Sagi D Jones SN Flavell RA Davis RJ Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway Science 2000 288 5467 870 874 10797012
  35. Deng X Xiao L Lang W Gao F Ruvolo P May WS Jr Novel role for JNK as a stress-activated Bcl2 kinase J Biol Chem 2001 276 26 23681 23688 11323415
  36. Xu P Davis RJ c-Jun NH2-terminal kinase is required for lineage-specific differentiation but not stem cell self-renewal Mol Cell Biol 2010 30 6 1329 1340 20065035 PMC2832508
  37. Ganiatsas S Kwee L Fujiwara Y Perkins A Ikeda T Labow MA Zon LI SEK1 deficiency reveals mitogen-activated protein kinase cascade crossregulation and leads to abnormal hepatogenesis Proc Natl Acad Sci USA 1998 95 12 6881 6886 9618507 PMC22670
  38. Nishina H Bachmann M Oliveira-dos-Santos AJ Kozieradzki I Fischer KD Odermatt B Wakeham A Shahinian A Takimoto H Bernstein A Impaired CD28-mediated interleukin 2 production and proliferation in stress kinase SAPK/ERK1 kinase (SEK1)/mitogen-activated protein kinase kinase 4 (MKK4)-deficient T lymphocytes J Exp Med 1997 186 6 941 953 9294148 PMC2199046
  39. Choukroun G Hajjar R Fry S del Monte F Haq S Guerrero JL Picard M Rosenzweig A Force T Regulation of cardiac hypertrophy in vivo by the stress-activated protein kinases/c-Jun NH(2)-terminal kinases J Clin Invest 1999 104 4 391 398 10449431 PMC408523
  40. Jiang Y Chen C Li Z Guo W Gegner JA Lin S Han J Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta) J Biol Chem 1996 271 30 17920 17926 8663524
  41. Lin A Minden A Martinetto H Claret FX Lange-Carter C Mercurio F Johnson GL Karin M Identification of a dual specificity kinase that activates the Jun kinases and p 38–Mpk2 Science 1995 268 5208 286 290 7716521
  42. Cunningham SC Gallmeier E Hucl T Dezentje DA Calhoun ES Falco G Abdelmohsen K Gorospe M Kern SE Targeted deletion of MKK4 in cancer cells: a detrimental phenotype manifests as decreased experimental metastasis and suggests a counterweight to the evolution of tumor-suppressor loss Cancer Res 2006 66 11 5560 5564 16740690
  43. Nakayama K Nakayama N Davidson B Katabuchi H Kurman RJ Velculescu VE Shih Ie M Wang TL Homozygous deletion of MKK4 in ovarian serous carcinoma Cancer Biol Ther 2006 5 6 630 634 16627982
  44. Hickson JA Huo D Vander Griend DJ Lin A Rinker-Schaeffer CW Yamada SD The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma Cancer Res 2006 66 4 2264 2270 16489030
  45. English JM Vanderbilt CA Xu S Marcus S Cobb MH Isolation of MEK5 and differential expression of alternatively spliced forms J Biol Chem 1995 270 48 28897 28902 7499418
  46. Zhou G Bao ZQ Dixon JE Components of a new human protein kinase signal transduction pathway J Biol Chem 1995 270 21 12665 12669 7759517
  47. Chao TH Hayashi M Tapping RI Kato Y Lee JD MEKK3 directly regulates MEK5 activity as part of the big mitogen-activated protein kinase 1 (BMK1) signaling pathway J Biol Chem 1999 274 51 36035 36038 10593883
  48. Kamakura S Moriguchi T Nishida E Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus J Biol Chem 1999 274 37 26563 26571 10473620
  49. Kato Y Kravchenko VV Tapping RI Han J Ulevitch RJ Lee JD BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C EMBO J 1997 16 23 7054 7066 9384584 PMC1170308
  50. Sun W Kesavan K Schaefer BC Garrington TP Ware M Johnson NL Gelfand EW Johnson GL MEKK2 associates with the adapter protein Lad/RIBP and regulates the MEK5-BMK1/ERK5 pathway J Biol Chem 2001 276 7 5093 5100 11073940
  51. Nakamura K Uhlik MT Johnson NL Hahn KM Johnson GL PB1 domain-dependent signaling complex is required for extracellular signal-regulated kinase 5 activation Mol Cell Biol 2006 26 6 2065 2079 16507987 PMC1430298
  52. Akaike M Che W Marmarosh NL Ohta S Osawa M Ding B Berk BC Yan C Abe J The hinge-helix 1 region of peroxisome proliferator-activated receptor gamma1 (PPARgamma1) mediates interaction with extracellular signal-regulated kinase 5 and PPARgamma1 transcriptional activation: involvement in flow-induced PPARgamma activation in endothelial cells Mol Cell Biol 2004 24 19 8691 8704 15367687 PMC516745
  53. English JM Pearson G Baer R Cobb MH Identification of substrates and regulators of the mitogen-activated protein kinase ERK5 using chimeric protein kinases J Biol Chem 1998 273 7 3854 3860 9461566
  54. Kasler HG Victoria J Duramad O Winoto A ERK5 is a novel type of mitogen-activated protein kinase containing a transcriptional activation domain Mol Cell Biol 2000 20 22 8382 8389 11046135 PMC102145
  55. Terasawa K Okazaki K Nishida E Regulation of c-Fos and Fra-1 by the MEK5-ERK5 pathway Genes Cells 2003 8 3 263 273 12622723
  56. Kato Y Tapping RI Huang S Watson MH Ulevitch RJ Lee JD Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor Nature 1998 395 6703 713 716 9790194
  57. Wang X Tournier C Regulation of cellular functions by the ERK5 signalling pathway Cell Signal 2006 18 6 753 760 16376520
  58. Nishimoto S Kusakabe M Nishida E Requirement of the MEK5-ERK5 pathway for neural differentiation in Xenopus embryonic development EMBO Rep 2005 6 11 1064 1069 16179948 PMC1371025
  59. Regan CP Li W Boucher DM Spatz S Su MS Kuida K Erk5 null mice display multiple extraembryonic vascular and embryonic cardiovascular defects Proc Natl Acad Sci USA 2002 99 14 9248 9253 12093914 PMC123126
  60. Hu B Ren D Su D Lin H Xian Z Wan X Zhang J Fu X Jiang L Diao D Expression of the phosphorylated MEK5 protein is associated with TNM staging of colorectal cancer BMC Cancer 2012 12 127 22458985 PMC3337320
  61. Mehta PB Jenkins BL McCarthy L Thilak L Robson CN Neal DE Leung HY MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion Oncogene 2003 22 9 1381 1389 12618764
  62. Esparis-Ogando A Diaz-Rodriguez E Montero JC Yuste L Crespo P Pandiella A Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2 Mol Cell Biol 2002 22 1 270 285 11739740 PMC134212
  63. Nagel S Burek C Venturini L Scherr M Quentmeier H Meyer C Rosenwald A Drexler HG MacLeod RA Comprehensive analysis of homeobox genes in Hodgkin lymphoma cell lines identifies dysregulated expression of HOXB9 mediated via ERK5 signaling and BMI1 Blood 2007 109 7 3015 3023 17148583
  64. Ramos-Nino ME Blumen SR Sabo-Attwood T Pass H Carbone M Testa JR Altomare DA Mossman BT HGF mediates cell proliferation of human mesothelioma cells through a PI3K/MEK5/Fra-1 pathway Am J Respir Cell Mol Biol 2008 38 2 209 217 17872495 PMC2214675
  65. Flaherty KT Robert C Hersey P Nathan P Garbe C Milhem M Demidov LV Hassel JC Rutkowski P Mohr P Improved survival with MEK inhibition in BRAF-mutated melanoma N Engl J Med 2012 367 2 107 114 22663011
  66. Wallace EM Lyssikatos JP Yeh T Winkler JD Koch K Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy Curr Top Med Chem 2005 5 2 215 229 15853648
  67. Yamaguchi T Kakefuda R Tajima N Sowa Y Sakai T Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo Int J Oncol 2011 39 1 23 31 21523318
  68. Gilmartin AG Bleam MR Groy A Moss KG Minthorn EA Kulkarni SG Rominger CM Erskine S Fisher KE Yang J GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition Clin Cancer Res 2011 17 5 989 1000 21245089
  69. Infante JR Fecher LA Falchook GS Nallapareddy S Gordon MS Becerra C DeMarini DJ Cox DS Xu Y Morris SR Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial Lancet Oncol 2012 13 8 773 781 22805291
  70. Kim K Kong SY Fulciniti M Li X Song W Nahar S Burger P Rumizen MJ Podar K Chauhan D Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo Br J Haematol 2010 149 4 537 549 20331454 PMC3418597
  71. Yoon J Koo KH Choi KY MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy Cancer Res 2011 71 2 445 453 21118963
  72. Macarulla T Tabernero J Cervantes A Roselló S Van Cutsem E Tejpar S Prenen H Martinelli E Troiani T Campana F Laffranchi B Jego V von Richter O Ciardiello F Phase I/II study of FOLFIRI plus the MEK1/2 inhibitor pimasertib (MSC1936369b) as second-line treatment for kras mutated metastatic colorectal cancer Ann Oncol 2012 23 Suppl 4 PD-0024 PMC4580393 25989270
  73. Yeh TC Marsh V Bernat BA Ballard J Colwell H Evans RJ Parry J Smith D Brandhuber BJ Gross S Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor Clin Cancer Res 2007 13 5 1576 1583 17332304
  74. Adjei AA Cohen RB Franklin W Morris C Wilson D Molina JR Hanson LJ Gore L Chow L Leong S Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers J Clin Oncol 2008 26 13 2139 2146 18390968 PMC2718422
  75. Bennouna J Lang I Valladares-Ayerbes M Boer K Adenis A Escudero P Kim TY Pover GM Morris CD Douillard JY A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens Invest New Drugs 2011 29 5 1021 1028 20127139
  76. Bodoky G Timcheva C Spigel DR La Stella PJ Ciuleanu TE Pover G Tebbutt NC A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy Invest New Drugs 2012 30 3 1216 1223 21594619
  77. Hainsworth JD Cebotaru CL Kanarev V Ciuleanu TE Damyanov D Stella P Ganchev H Pover G Morris C Tzekova V A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens J Thorac Oncol 2010 5 10 1630 1636 20802351
  78. Hayes DN Lucas AS Tanvetyanon T Krzyzanowska MK Chung CH Murphy BA Gilbert J Mehra R Moore DT Sheikh A Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements Clin Cancer Res 2012 18 7 2056 2065 22241789 PMC5157199
  79. Kirkwood JM Bastholt L Robert C Sosman J Larkin J Hersey P Middleton M Cantarini M Zazulina V Kemsley K Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma Clin Cancer Res 2012 18 2 555 567 22048237 PMC3549298
  80. O’Neil BH Goff LW Kauh JS Strosberg JR Bekaii-Saab TS Lee RM Kazi A Moore DT Learoyd M Lush RM Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma J Clin Oncol 2011 29 17 2350 2356 21519015 PMC3107750
  81. Janne PA Shaw AT Pereira JR Jeannin G Vansteenkiste J Barrios C Franke FA Grinsted L Zazulina V Smith P Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study Lancet Oncol 2013 14 1 38 47 23200175
  82. Farley J Brady WE Vathipadiekal V Lankes HA Coleman R Morgan MA Mannel R Yamada SD Mutch D Rodgers WH Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study Lancet Oncol 2013 14 2 134 140 23261356 PMC3627419
  83. Ho AL Grewal RK Leboeuf R Sherman EJ Pfister DG Deandreis D Pentlow KS Zanzonico PB Haque S Gavane S Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer N Engl J Med 2013 368 7 623 632 23406027 PMC3615415
  84. Barrett SD Bridges AJ Dudley DT Saltiel AR Fergus JH Flamme CM Delaney AM Kaufman M LePage S Leopold WR The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901 Bioorg Med Chem Lett 2008 18 24 6501 6504 18952427
  85. Henderson YC Chen Y Frederick MJ Lai SY Clayman GL MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo Mol Cancer Ther 2010 9 7 1968 1976 20587665 PMC2935263
  86. Lorusso PM Adjei AA Varterasian M Gadgeel S Reid J Mitchell DY Hanson L DeLuca P Bruzek L Piens J Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies J Clin Oncol 2005 23 23 5281 5293 16009947
  87. Sheth PR Liu Y Hesson T Zhao J Vilenchik L Liu YH Mayhood TW Le HV Fully activated MEK1 exhibits compromised affinity for binding of allosteric inhibitors U0126 and PD0325901 Biochemistry 2011 50 37 7964 7976 21793567
  88. Haura EB Ricart AD Larson TG Stella PJ Bazhenova L Miller VA Cohen RB Eisenberg PD Selaru P Wilner KD A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer Clin Cancer Res 2010 16 8 2450 2457 20332327
  89. Iverson C Larson G Lai C Yeh LT Dadson C Weingarten P Appleby T Vo T Maderna A Vernier JM RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer Cancer Res 2009 69 17 6839 6847 19706763
  90. Chang Q Chapman MS Miner JN Hedley DW Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts BMC Cancer 2010 10 515 20920162 PMC2955043
  91. Dong Q Dougan DR Gong X Halkowycz P Jin B Kanouni T O’Connell SM Scorah N Shi L Wallace MB Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer Bioorg Med Chem Lett 2011 21 5 1315 1319 21310613
  92. von Euw E Atefi M Attar N Chu C Zachariah S Burgess BL Mok S Ng C Wong DJ Chmielowski B Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines Mol Cancer 2012 11 22 22515704 PMC3444881
  93. Martinez-Garcia M Banerji U Albanell J Bahleda R Dolly S Kraeber-Bodere F Rojo F Routier E Guarin E Xu ZX First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors Clin Cancer Res 2012 18 17 4806 4819 22761467
  94. Isshiki Y Kohchi Y Iikura H Matsubara Y Asoh K Murata T Kohchi M Mizuguchi E Tsujii S Hattori K Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent Bioorg Med Chem Lett 2011 21 6 1795 1801 21316218
  95. Leijen S Middleton MR Tresca P Kraeber-Bodere F Dieras V Scheulen ME Gupta A Lopez-Valverde V Xu ZX Rueger R Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors Clin Cancer Res 2012 18 17 4794 4805 22767668
  96. Wong H Vernillet L Peterson A Ware JA Lee L Martini JF Yu P Li C Del Rosario G Choo EF Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor Clin Cancer Res 2012 18 11 3090 3099 22496205
  97. Choo EF Belvin M Boggs J Deng Y Hoeflich KP Ly J Merchant M Orr C Plise E Robarge K Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions Drug Metab Dispos 2012 40 5 919 927 22315332
  98. Wallace EM Lyssikatos J Blake JF Marlow A Greschuk J Yeh TC Callejo M Marsh V Poch G Otten J Hingorani G Winski SL Anderson DA Lee P Winkler J Koch K Davies BR Jones DC Logie A Curtis NJ Chresta CM Smith PD Robinson DT AZD8330 (ARRY-424704): Preclinical evaluation of a potent, selective MEK 1/2 inhibitor currently in phase I trials Cancer Res 2009 AACR Annual Meeting Proceedings 2009
  99. Cohen RB Aamdal S Nyakas M Cavallin M Green D Learoyd M Smith I Kurzrock R A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies Eur J Cancer 2013 49 1521 1529 23433846
  100. Ponti G Tomasi A Pellacani G Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma J Hematol Oncol 2012 5 1 60 23031422 PMC3473234
  101. WeiSZ L Efferth T Polo-like kinase 1 as target for cancer therapy Exp Hematol Oncol 2012 1 1 38 23227884 PMC3533518
  102. Lamba G Gupta R Lee B Ambrale S Liu D Current management and prognostic features for gastrointestinal stromal tumor (GIST) Exp Hematol Oncol 2012 1 1 14 23210689 PMC3514103

Cited by

Sorted by citations

Authors
Akinleye, A., Furqan, M., Mukhi, N., Ravella, P., & Liu, D.
Affiliations
Westchester Medical Center (US)
Corresponding author
Liu, Delong
ORCID
Venue
Journal of Hematology & Oncology
Publisher
Springer Science and Business Media LLC
Published
2013-04-12
Volume
6
Issue
1
Pages
27-27
ISSN
1756-8722 (ISSN-L)
DOI
10.1186/1756-8722-6-27
PMC
PMC3626705
OpenAlex
W2160181672
Cited by
291
References
4
Citations by year
2026: 10 · 2025: 21 · 2024: 25 · 2023: 12 · 2022: 9 · 2021: 16 · 2020: 14 · 2019: 13 · 2018: 20 · 2017: 29 · 2016: 33 · 2015: 47 · 2014: 30 · 2013: 12
FWCI
3.86
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Journal of Hematology & Oncology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Touro Scholar (Touro College) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords
MEK inhibitors, MAPK signaling, MEK1, MEK2, trametinib, selumetinib, BRAF V600 mutation, metastatic melanoma, non-small cell lung cancer, docetaxel combination, pimasertib, refametinib, PD0325901, MEK162, clinical trials, drug development
MeSH terms
Humans, Neoplasms, Protein Kinase Inhibitors, MAP Kinase Kinase 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review